Skip to main content

Advertisement

Table 2 The relationship between MYC, BCL2 and BCL6 genetic alteration and clinical features

From: Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma

  MYC EC BCL2 EC BCL6 EC Atypical DHL/THL Atypical DHL/THL DHL + THL P Atypical DHL/THL DEL P
+ P + P + P + P
n(%) n(%)   n(%) n(%)   n (%) n(%)   n(%) n(%)   n(%) n(%)   n(%) n(%)  
n = 82 n = 81 n = 78 n = 49 n = 18 n = 32
Age
 Median (range) 60(18–69) 61(2–86)   61(2–80) 60 (18–86)   57 (28–82) 63(2–86)   61(28–69) 63(29–86)   61(28–69) 60 (54–73)   61(28–69) 63(28–86)  
 > 60 4(36.4) 37(52.1) 0.519* 11(52.4) 29(48.3) 0.749 7(38.9) 35(58.3) 0.147 5(50.0) 23(59.0) 0.609 5(50.0) 3(37.5) 0.664* 5(50.0) 12(54.5) 0.811
Sex
 Male 6(54.5) 30(42.3) 0.445 12(57.1) 24(40.0) 0.174 12(66.7) 24(40.0) 0.047 6(60.0) 13(33.3) 0.156* 6(60.0) 5(62.5) > 0.999* 4(40.0) 9(40.9) > 0.999*
 Female 5(45.5) 41(57.7)   9(42.9) 36(60.0)   6(33.3) 36(60.0)   4(40.0) 26(66.7)   4(40.0) 3(37.5)   6(60.0) 13(59.1)  
 Ann Arbor stage> 2 10(90.9) 51(71.8) 0.274* 17(81.0) 43(71.7) 0.565* 14(77.8) 43(71.7) 0.766* 9(90.0) 26(66.7) 0.244* 9(90.0) 8(100.0) > 0.999* 9(90.0) 16(72.7) 0.387*
 Extranodal sites≥2 6(54.5) 38(53.5) 0.949 14(66.7) 32(53.3) 0.288 11(61.1) 31(51.7) 0.481 5(50.0) 19(48.7) 0.942 5(50.0) 6(75.0) 0.367* 5(50.0) 12(54.5) 0.811
 Elevated serum LDH 7(63.6) 33(47.8) 0.518* 9(45.0) 32(54.2) 0.475 9(52.9) 26(44.1) 0.518 6(60.0) 19(48.7) 0.725* 6(60.0) 5(62.5) > 0.999* 6(60.0) 14(66.7) > 0.999*
 ECOG PS ≥ 2 2(18.2) 13(18.3) > 0.999* 5(23.8) 13(21.7) 0.839 4(22.2) 11(18.3) 0.739* 2(20.0) 7(17.9) > 0.999* 2(20.0) 5(62.5) 0.145* 2(20.0) 3(13.6) 0.637*
 IPI ≥ 3 7(63.6) 35(49.3) 0.520* 11(52.4) 33(55.0) 0.836 9(50.0) 31(51.7) 0.901 6(60.0) 18(46.2) 0.496* 6(60.0) 7(87.5) 0.314* 6(60.0) 13(59.1) > 0.999*
 B symptoms 9(81.8) 29(40.8) 0.020* 13(61.9) 26(43.3) 0.143 9(50.0) 28(46.7) 0.804 7(70.0) 16(41.0) 0.157* 7(70.0) 6(75.0) > 0.999* 7(70.0) 10(45.5) 0.265*
 Marrow involvement 3(27.3) 6(8.5) 0.097* 7(33.3) 3(5.0) 0.002* 4(22.2) 9(15.0) 0.483* 4(40.0) 1(2.6) 0.004* 4(40.0) 6(75.0) 0.188* 4(40.0) 4(18.2) 0.218*
 Nervous involvement 2(18.2) 7(9.9) 0.347* 5(23.8) 5(8.3) 0.064 2(11.1) 4(6.7) 0.617* 2(20.0) 2(5.1) 0.180* 2(20.0) 1(12.5) > 0.999* 2(20.0) 2(9.1) 0.572*
Treatment
 R-CHOP 7(63.6) 35(49.3)   12(57.1) 29(48.3)   8(44.4) 33(55.0)   6(60.0) 21(53.8) 0.444 6(60.0) 5(62.5) 0.460 6(60.0) 9(40.9) 0.662
 R-CHOPE 4(36.4) 24(33.8)   8(38.1) 19(31.7)   7(38.9) 19(31.7)   4(40.0) 10(2.6)   4(40.0) 2(25.0)   4(40.0) 11(50.0)  
 Resection 0(0) 10(14.1)   1(4.8) 9(15.0)   2(11.1) 7(11.7)   0(0) 7(17.9)   0(0) 0(0)   0(0) 1(4.5)  
 No therapy 0(0) 2(2.8)   0(0) 3(5.0)   1(5.6) 1(1.7)   0(0) 1(2.6)   0(0) 1(12.5)   0(0) 1(4.5)  
 ASCT (total) 2(18.2) 12(16.9) > 0.999* 3(14.3) 10(16.7) > 0.999* 2(11.1) 9(15.0) > 0.999* 1(10.0) 4(10.3) > 0.999* 1(10.0) 2(25.0) 0.559* 1(10.0) 6(27.3) 0.387*
Treatment response
 CR 5(45.5) 37(55.2) 0.132 9(42.9) 32(57.1) 0.458 9(56.3) 30(51.7) 0.786 5(50.0) 21(56.8) 0.071 5(50.0) 1(12.5) 0.207 5(50.0) 10(47.6) 0.096
 PR 3(27.3) 25(37.3)   8(38.1) 18(32.1)   5(31.3) 23(39.7)   2(20.0) 14(37.8)   4(50.0) 2(20.0)   2(20.0) 10(47.6)  
 SD 3(27.3) 5(7.5)   4(19.0) 6(10.7)   2(12.5) 5(8.6)   3(30.0) 2(5.4)   3(30.0) 3(37.5)   3(30.0) 1(4.8)  
 Relapse 3(27.3) 10(14.7) 0.377* 4(19.0) 11(19.3) > 0.999* 4(23.5) 9(15.5) 0.475* 3(30.0) 6(16.2) 0.377* 3(30.0) 3(37.5) > 0.999* 3(30.0) 2(9.5) 0.296*
  1. EC extra copies, DHL double hit lymphoma, THL triple hit lymphoma, DEL double expressor lymphoma, LDH lactate dehydrogenase, ECOG Eastern Cooperative Oncology Group, PS performance status, IPI international prognostic index, ASCT autologous stem cell transplantation, CR complete response/remission, PR partial response/remission, SD,stable disease
  2. *Fisher’s exact test